EP4716699A2 - Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation - Google Patents

Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation

Info

Publication number
EP4716699A2
EP4716699A2 EP24811788.9A EP24811788A EP4716699A2 EP 4716699 A2 EP4716699 A2 EP 4716699A2 EP 24811788 A EP24811788 A EP 24811788A EP 4716699 A2 EP4716699 A2 EP 4716699A2
Authority
EP
European Patent Office
Prior art keywords
tcr
polypeptide
peptide
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24811788.9A
Other languages
German (de)
English (en)
Inventor
Ke Pan
Cassian Yee
Yulun CHIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of EP4716699A2 publication Critical patent/EP4716699A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne des récepteurs de lymphocytes T (TCR) génétiquement modifiés, des cellules comprenant les TCR, et des méthodes de production et d'utilisation des TCR. La présente invention concerne des TCR qui reconnaissent spécifiquement un ou des épitopes de l'antigène tumoral TBXT. En conséquence, des aspects de la divulgation concernent des récepteurs de lymphocytes T (TCR) génétiquement modifiés, des acides nucléiques codant pour les TCR, et des cellules comprenant les acides nucléiques et les TCR. La divulgation concerne également des compositions comprenant les cellules, les acides nucléiques ou les TCR génétiquement modifiés de la divulgation, des méthodes de fabrication des cellules et des méthodes d'utilisation des modes de réalisation de la divulgation dans des traitements thérapeutiques.
EP24811788.9A 2023-05-22 2024-05-21 Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation Pending EP4716699A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363468208P 2023-05-22 2023-05-22
US202363545670P 2023-10-25 2023-10-25
PCT/US2024/030400 WO2024243227A2 (fr) 2023-05-22 2024-05-21 Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation

Publications (1)

Publication Number Publication Date
EP4716699A2 true EP4716699A2 (fr) 2026-04-01

Family

ID=93590447

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24811788.9A Pending EP4716699A2 (fr) 2023-05-22 2024-05-21 Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation

Country Status (2)

Country Link
EP (1) EP4716699A2 (fr)
WO (1) WO2024243227A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
CA2998270A1 (fr) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr et utilisations associees
EP3211003A1 (fr) * 2016-02-24 2017-08-30 Institut Pasteur Récepteurs de lymphocytes t à partir du répertoire spécifique au vih, moyens pour leur production et leurs utilisations thérapeutiques
EP3962939A4 (fr) * 2019-05-03 2023-05-17 Gigamune, Inc. Cellules modifiées exprimant des récepteurs des lymphocytes t antitumoraux et leurs méthodes d'utilisation
KR20240005714A (ko) * 2021-03-29 2024-01-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Sars-cov-2 항원을 표적화하는 펩티드 및 조작된 t 세포 수용체 및 사용 방법

Also Published As

Publication number Publication date
WO2024243227A2 (fr) 2024-11-28
WO2024243227A3 (fr) 2025-04-24

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたｔ細胞受容体および使用の方法
US20240009241A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
EP4423116A1 (fr) Procédés et compositions pour le traitement du glioblastome
WO2024123975A2 (fr) Récepteur des lymphocytes t reconnaissant un épitope foxm1 non muté présenté sur hla-a * 02 : 01
JP7827645B2 (ja) 操作されたｔ細胞受容体および使用の方法
US20230143031A1 (en) Engineered t cell receptors and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
EP4716699A2 (fr) Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation
US20260125448A1 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
WO2026019786A1 (fr) Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène de brachyury et procédés d'utilisation
WO2025101705A1 (fr) Peptides et récepteurs de lymphocytes t modifiés ciblant un antigène de mélanome préférentiellement exprimé dans un antigène de tumeurs et procédés d'utilisation
WO2025096983A1 (fr) Peptides et récepteurs de lymphocytes t génétiquement modifiés ciblant l'antigène tpx2 et procédés d'utilisation
EP4422651A2 (fr) Peptides et récepteurs de lymphocytes t modifiés ciblant l'antigène mage-a4 et méthodes d'utilisation
WO2024123794A2 (fr) Récepteur de lymphocytes t reconnaissant une mutation her2 présentée sur hla-a*02:01 et ses procédés d'utilisation
US20240009240A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
HK40113193A (zh) 靶向ndc80抗原的肽和经改造t细胞受体及使用方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR